Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mads Kirchheiner Rasmussen

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|September 28, 2023
Lasse Rishøj, Mads Kirchheiner Rasmussen, Trine Bertelsen
Ugeskrift for Laeger|November 9, 2018
[A woman with hidrosadenitis suppurativa underwent multiple operations for abscesses]Birgitte Skjærbæk Aggerholm, Mads Kirchheiner Rasmussen, Mette Meinert
JAMA Dermatology|October 22, 2025
Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or UstekinumabChristopher Willy Schwarz, Mads Kirchheiner Rasmussen, Trine Bertelsen, et al.
Acta Dermato-Venereologica|September 26, 2018
The Importance of Achieving Clear or Almost Clear Skin for Patients: Results from the Nordic Countries of the GlobalMads Kirchheiner Rasmussen, Martin Enger, Anna-Karin Dahlborn, et al.
Frontiers in Immunology|March 2, 2026
Transcriptomic profiling reveals distinct molecular signatures among lesion types in hidradenitis suppurativaHakim Ben Abdallah, Christine Daugaard, Louise Schøsler, et al.
Clinical Case Reports|October 22, 2020
Idiopathic hypereosinophilic syndrome: A rare diagnosis in childrenKristine Appel Uldall Pallesen, Troels Herlin, Mette Holm, et al.
Acta Dermato-Venereologica|October 4, 2019
Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide StudyNikolai Dyrberg Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, et al.
Acta Dermato-Venereologica|October 13, 2021
Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort StudyChristopher Willy Schwarz, Nikolai Loft, Mads Kirchheiner Rasmussen, et al.
JAMA Dermatology|April 7, 2021
Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With PsoriasisNikolai Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, et al.
Acta Dermato-Venereologica|December 15, 2020
Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide StudyNikolai Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|September 28, 2023
Lasse Rishøj, Mads Kirchheiner Rasmussen, Trine Bertelsen
Ugeskrift for Laeger|November 9, 2018
[A woman with hidrosadenitis suppurativa underwent multiple operations for abscesses]Birgitte Skjærbæk Aggerholm, Mads Kirchheiner Rasmussen, Mette Meinert
JAMA Dermatology|October 22, 2025
Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or UstekinumabChristopher Willy Schwarz, Mads Kirchheiner Rasmussen, Trine Bertelsen, et al.
Acta Dermato-Venereologica|September 26, 2018
The Importance of Achieving Clear or Almost Clear Skin for Patients: Results from the Nordic Countries of the GlobalMads Kirchheiner Rasmussen, Martin Enger, Anna-Karin Dahlborn, et al.
Frontiers in Immunology|March 2, 2026
Transcriptomic profiling reveals distinct molecular signatures among lesion types in hidradenitis suppurativaHakim Ben Abdallah, Christine Daugaard, Louise Schøsler, et al.
Clinical Case Reports|October 22, 2020
Idiopathic hypereosinophilic syndrome: A rare diagnosis in childrenKristine Appel Uldall Pallesen, Troels Herlin, Mette Holm, et al.
Acta Dermato-Venereologica|October 4, 2019
Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide StudyNikolai Dyrberg Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, et al.
Acta Dermato-Venereologica|October 13, 2021
Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort StudyChristopher Willy Schwarz, Nikolai Loft, Mads Kirchheiner Rasmussen, et al.
JAMA Dermatology|April 7, 2021
Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With PsoriasisNikolai Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, et al.
Acta Dermato-Venereologica|December 15, 2020
Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide StudyNikolai Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, et al.
Pageof 2